395 related articles for article (PubMed ID: 16048934)
1. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.
Kusuma CM; Kokai-Kun JF
Antimicrob Agents Chemother; 2005 Aug; 49(8):3256-63. PubMed ID: 16048934
[TBL] [Abstract][Full Text] [Related]
2. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin.
Sader HS; Fritsche TR; Jones RN
Antimicrob Agents Chemother; 2006 Jul; 50(7):2330-6. PubMed ID: 16801409
[TBL] [Abstract][Full Text] [Related]
3. Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin.
Placencia FX; Kong L; Weisman LE
Pediatr Res; 2009 Apr; 65(4):420-4. PubMed ID: 19127212
[TBL] [Abstract][Full Text] [Related]
4. Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit.
Dajcs JJ; Hume EB; Moreau JM; Caballero AR; Cannon BM; O'Callaghan RJ
Invest Ophthalmol Vis Sci; 2000 May; 41(6):1432-7. PubMed ID: 10798659
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing, China.
Yang XY; Li CR; Lou RH; Wang YM; Zhang WX; Chen HZ; Huang QS; Han YX; Jiang JD; You XF
J Med Microbiol; 2007 Jan; 56(Pt 1):71-76. PubMed ID: 17172520
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
7. Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin.
Graham S; Coote PJ
J Antimicrob Chemother; 2007 Apr; 59(4):759-62. PubMed ID: 17324959
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.
Fritsche TR; Rhomberg PR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):399-403. PubMed ID: 18178361
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus.
LaPlante KL
Diagn Microbiol Infect Dis; 2007 Apr; 57(4):413-8. PubMed ID: 17141452
[TBL] [Abstract][Full Text] [Related]
10. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces.
Wu JA; Kusuma C; Mond JJ; Kokai-Kun JF
Antimicrob Agents Chemother; 2003 Nov; 47(11):3407-14. PubMed ID: 14576095
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates.
Hussain FM; Boyle-Vavra S; Shete PB; Daum RS
J Infect Dis; 2002 Sep; 186(5):661-7. PubMed ID: 12195353
[TBL] [Abstract][Full Text] [Related]
12. [Investigation of reduced vancomycin susceptibility in methicillin-resistant staphylococci].
Kuşcu F; Oztürk DB; Gürbüz Y; Tütüncü EE; Sencan I; Gül S
Mikrobiyol Bul; 2011 Apr; 45(2):248-57. PubMed ID: 21644067
[TBL] [Abstract][Full Text] [Related]
13. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.
Pillai SK; Wennersten C; Venkataraman L; Eliopoulos GM; Moellering RC; Karchmer AW
Clin Infect Dis; 2009 Oct; 49(8):1169-74. PubMed ID: 19769538
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008).
Sader HS; Becker HK; Moet GJ; Jones RN
Diagn Microbiol Infect Dis; 2010 Mar; 66(3):329-31. PubMed ID: 20159377
[TBL] [Abstract][Full Text] [Related]
15. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
Appelbaum PC
Int J Antimicrob Agents; 2007 Nov; 30(5):398-408. PubMed ID: 17888634
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of laboratory-generated vancomycin intermediate resistant Staphylococcus aureus strains.
Bhateja P; Purnapatre K; Dube S; Fatma T; Rattan A
Int J Antimicrob Agents; 2006 Mar; 27(3):201-11. PubMed ID: 16417988
[TBL] [Abstract][Full Text] [Related]
17. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1997 Aug; 46(33):765-6. PubMed ID: 9272582
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
Barcia-Macay M; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2006 Dec; 58(6):1177-84. PubMed ID: 17062609
[TBL] [Abstract][Full Text] [Related]
19. [Susceptibility of Staphylococcus aureus biofilms to vancomycin, gemtamicin and rifampin].
Kotulová D; Slobodníková L
Epidemiol Mikrobiol Imunol; 2010 Apr; 59(2):80-7. PubMed ID: 20586169
[TBL] [Abstract][Full Text] [Related]
20. First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand.
Trakulsomboon S; Danchaivijitr S; Rongrungruang Y; Dhiraputra C; Susaemgrat W; Ito T; Hiramatsu K
J Clin Microbiol; 2001 Feb; 39(2):591-5. PubMed ID: 11158112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]